Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 1,590 Shares

Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 1,590 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $30.48, for a total value of $48,463.20. Following the sale, the insider now directly owns 251,033 shares of the company's stock, valued at $7,651,485.84. This represents a 0.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, February 5th, Carl Dambkowski sold 3,520 shares of Apogee Therapeutics stock. The shares were sold at an average price of $40.69, for a total transaction of $143,228.80.
• On Thursday, January 2nd, Carl Dambkowski sold 4,085 shares of Apogee Therapeutics stock. The stock was sold at an average price of $46.94, for a total value of $191,749.90.
• On Wednesday, December 11th, Carl Dambkowski sold 4,540 shares of Apogee Therapeutics stock. The shares were sold at an average price of $48.76, for a total transaction of $221,370.40.

Apogee Therapeutics Stock Performance

NASDAQ:APGE traded up $2.73 during mid-day trading on Tuesday, hitting $40.27. 988,378 shares of the company's stock traded hands, compared to its average volume of 494,960. The company has a fifty day moving average of $38.68 and a 200 day moving average of $46.77. Apogee Therapeutics, Inc. has a twelve month low of $29.10 and a twelve month high of $72.29. The company has a market capitalization of $1.81 billion, a P/E ratio of -16.64 and a beta of 2.46.

Remove Ads

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($1.19) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.25). On average, research analysts expect that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Apogee Therapeutics

Several hedge funds have recently made changes to their positions in APGE. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Apogee Therapeutics in the fourth quarter valued at approximately $6,521,000. GF Fund Management CO. LTD. acquired a new stake in Apogee Therapeutics during the fourth quarter worth about $43,000. Neo Ivy Capital Management purchased a new position in shares of Apogee Therapeutics during the 4th quarter valued at approximately $1,745,000. Woodline Partners LP lifted its stake in shares of Apogee Therapeutics by 4.0% in the 4th quarter. Woodline Partners LP now owns 1,015,608 shares of the company's stock valued at $46,007,000 after purchasing an additional 39,453 shares during the period. Finally, Soleus Capital Management L.P. purchased a new stake in Apogee Therapeutics during the fourth quarter worth $3,171,000. 79.04% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have issued reports on APGE shares. Guggenheim reaffirmed a "buy" rating on shares of Apogee Therapeutics in a research report on Monday, February 10th. Canaccord Genuity Group began coverage on Apogee Therapeutics in a research report on Monday, November 25th. They set a "buy" rating and a $89.00 price objective on the stock. Wedbush reiterated an "outperform" rating and issued a $90.00 target price on shares of Apogee Therapeutics in a report on Tuesday. Finally, Canaccord Genuity Group assumed coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They set a "buy" rating and a $89.00 price target for the company. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Apogee Therapeutics presently has a consensus rating of "Buy" and an average price target of $91.60.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.